• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Age-related macular degeneration foils drugmakers.

作者信息

Dolgin Elie

出版信息

Nat Biotechnol. 2017 Nov 9;35(11):1000-1001. doi: 10.1038/nbt1117-1000.

DOI:10.1038/nbt1117-1000
PMID:29121027
Abstract
摘要

相似文献

1
Age-related macular degeneration foils drugmakers.年龄相关性黄斑变性使制药商受挫。
Nat Biotechnol. 2017 Nov 9;35(11):1000-1001. doi: 10.1038/nbt1117-1000.
2
Regeneron focuses on age-related macular degeneration.
Chem Biol. 2008 Apr;15(4):303-4. doi: 10.1016/j.chembiol.2008.04.002.
3
Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.关于雷珠单抗（一种抗血管内皮生长因子抗原结合片段）作为新生血管性年龄相关性黄斑变性治疗药物的研发情况。
Retina. 2007 Oct;27(8):1154-6; author reply 1156-8. doi: 10.1097/IAE.0b013e3180ca7daf.
4
Comparison of age-related macular degeneration treatment trials: what did we learn?年龄相关性黄斑变性治疗试验的比较：我们学到了什么？
Retina. 2012 Mar;32(3):413-6. doi: 10.1097/IAE.0B013E3182493C05.
5
[New perspectives in the approach to age-related macular degeneration].[年龄相关性黄斑变性治疗的新视角]
Arch Soc Esp Oftalmol. 2015 Mar;90 Suppl 1:11-4. doi: 10.1016/S0365-6691(15)30004-6.
6
Deal watch: Alcon licenses complement pathway inhibitor for macular degeneration.交易观察：爱尔康获得黄斑变性补体通路抑制剂许可。
Nat Rev Drug Discov. 2009 Dec;8(12):922. doi: 10.1038/nrd3063.
7
[Bevacizumab versus ranibizumab: a draw?].
J Fr Ophtalmol. 2012 Feb;35(2):79-81. doi: 10.1016/j.jfo.2011.06.003. Epub 2011 Oct 26.
8
New hope for dry AMD?干性年龄相关性黄斑变性有新希望了？
Nat Rev Drug Discov. 2013 Jul;12(7):501-2. doi: 10.1038/nrd4038.
9
Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy.雷珠单抗治疗新生血管性年龄相关性黄斑变性的临床疗效观察。
Br J Ophthalmol. 2011 Apr;95(4):530-3. doi: 10.1136/bjo.2009.171868. Epub 2010 Oct 11.
10
[VEGF in age-related macular degeneration. Part II. VEGF inhibitors use in age-related macular degeneration treatment].[血管内皮生长因子与年龄相关性黄斑变性。第二部分。血管内皮生长因子抑制剂在年龄相关性黄斑变性治疗中的应用]
Klin Oczna. 2007;109(1-3):97-100.

引用本文的文献

1
Complement-targeted therapeutics: Are we there yet, or just getting started?靶向补体的疗法：我们已经成功了，还是才刚刚开始？
Eur J Immunol. 2024 Dec;54(12):e2350816. doi: 10.1002/eji.202350816. Epub 2024 Sep 12.
2
Mitochondria-dependent phase separation of disease-relevant proteins drives pathological features of age-related macular degeneration.线粒体依赖性疾病相关蛋白液-液相分离驱动年龄相关性黄斑变性的病理特征。
JCI Insight. 2021 May 10;6(9):142254. doi: 10.1172/jci.insight.142254.
3
Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions.

本文引用的文献

1
Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration.靶向替代补体途径的因子 D 可减缓与年龄相关性黄斑变性相关的地图状萎缩进展。
Sci Transl Med. 2017 Jun 21;9(395). doi: 10.1126/scitranslmed.aaf1443.
2
Iron Toxicity in the Retina Requires Alu RNA and the NLRP3 Inflammasome.视网膜中的铁毒性需要Alu RNA和NLRP3炎性小体。
Cell Rep. 2015 Jun 23;11(11):1686-93. doi: 10.1016/j.celrep.2015.05.023. Epub 2015 Jun 11.
3
Stem cell therapy clears first hurdle in AMD.
靶向视网膜中的补体成分 C3 和 C5：关键概念和遗留问题。
Prog Retin Eye Res. 2021 Jul;83:100936. doi: 10.1016/j.preteyeres.2020.100936. Epub 2020 Dec 13.
4
Implantable anti-angiogenic scaffolds for treatment of neovascular ocular pathologies.用于治疗新生血管性眼病的可植入抗血管生成支架。
Drug Deliv Transl Res. 2020 Oct;10(5):1191-1202. doi: 10.1007/s13346-020-00753-0.
5
Complement Activation Levels Are Related to Disease Stage in AMD.补体激活水平与 AMD 的疾病阶段有关。
Invest Ophthalmol Vis Sci. 2020 Mar 9;61(3):18. doi: 10.1167/iovs.61.3.18.
6
Diacron reactive oxygen metabolites and biological antioxidant potential tests for patients with age-related macular degeneration.用于年龄相关性黄斑变性患者的二氢肌酐活性氧代谢物和生物抗氧化能力检测。
BMC Ophthalmol. 2020 Feb 18;20(1):56. doi: 10.1186/s12886-020-01334-y.
7
Complement system and age-related macular degeneration: drugs and challenges.补体系统与年龄相关性黄斑变性：药物与挑战
Drug Des Devel Ther. 2019 Jul 19;13:2413-2425. doi: 10.2147/DDDT.S206355. eCollection 2019.
8
Negative Regulators of Angiogenesis, Ocular Vascular Homeostasis, and Pathogenesis and Treatment of Exudative AMD.血管生成、眼血管稳态以及渗出性年龄相关性黄斑变性发病机制与治疗的负调控因子
J Ophthalmic Vis Res. 2018 Oct-Dec;13(4):470-486. doi: 10.4103/jovr.jovr_67_18.
9
Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases.靶向补体介导疾病中的替代和凝集素途径成分的策略。
Front Immunol. 2018 Aug 8;9:1851. doi: 10.3389/fimmu.2018.01851. eCollection 2018.
10
Aberrant early endosome biogenesis mediates complement activation in the retinal pigment epithelium in models of macular degeneration.异常早期内体生物发生在黄斑变性模型的视网膜色素上皮中介导补体激活。
Proc Natl Acad Sci U S A. 2018 Sep 4;115(36):9014-9019. doi: 10.1073/pnas.1805039115. Epub 2018 Aug 20.
干细胞疗法跨越了年龄相关性黄斑变性的首个障碍。
Nat Biotechnol. 2014 Dec;32(12):1173-4. doi: 10.1038/nbt1214-1173.
4
Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity.核苷类逆转录酶抑制剂具有内在的抗炎活性。
Science. 2014 Nov 21;346(6212):1000-3. doi: 10.1126/science.1261754.